<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110330</url>
  </required_header>
  <id_info>
    <org_study_id>CR012910</org_study_id>
    <secondary_id>KETFUN3001</secondary_id>
    <nct_id>NCT01110330</nct_id>
  </id_info>
  <brief_title>An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as
      effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo
      in treating patients with Tinea pedis, a skin infection commonly known as &quot;athlete's foot&quot;
      that is caused by a kind of mold called a fungus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), double-blind (neither the physician nor
      the patient knows the name of the assigned treatment), multicentre study in Poland and the
      United Kingdom designed to assess the mycological (fungal) cure rate and clinical efficacy of
      a new formulation of ketoconazole 2% cream (F126) with the current formulation of
      ketoconazole 2% cream (Nizoral) (F012) compared with placebo cream in patients with
      symptomatic uncomplicated interdigital (between the toes) Tinea pedis, a skin infection
      commonly known as &quot;athlete's foot&quot; that is caused by a kind of mold called a fungus.
      Approximately 548 patients who have symptomatic uncomplicated interdigital Tinea pedis
      confirmed by positive potassium hydroxide (KOH) microscopy (examination using a microscope)
      and mycological (fungal) culture will be randomized to receive 1 of 2 formulations of
      ketoconazole 2% cream (formulation F012 or F126) or placebo cream. There will be 4 study
      visits during the study. At Visit 1 (baseline), patients will sign the informed consent and
      be assessed for mycological and clinical signs and symptoms of Tinea pedis. Baseline
      demographics (age, race, etc), medical history and medication (s) that the patient is
      currently taking will be recorded. Patients will be issued with a tube of the cream and
      instructed to apply the cream sparingly to all affected areas of the foot (or feet), once
      daily (at night or in the evenings) for a total of 4 weeks according to protocol-specified
      guidelines. During the 4-week treatment period patients will return to the study every 2
      weeks to be assessed for clinical signs and symptoms. After the 4-week treatment period,
      patients will continue participation in the study for an additional 2 weeks without
      medication. Patients will return then return to the study center for a final visit (Visit 4,
      Week 6) at which time skin scrapings will be sampled from interdigital spaces on both feet
      for KOH microscopy and mycological culture. The primary efficacy endpoint is to determine
      whether a new formulation of ketoconazole 2% cream is equivalent (or as effective) as the
      current formulation of ketoconazole 2% cream (Nizoral) compared to a placebo cream in
      achieving a mycological cure (defined as negative KOH microscopy and negative mycological
      culture) following 4 weeks of treatment. The primary outcome measure in the study is a
      mycological cure (defined as negative KOH microscopy and negative mycological culture) at
      week 6. Patients will be monitored for safety (occurrence of adverse events, use of
      concomitant medications, and reasons for premature discontinuation from the study) from Visit
      1 through Visit 4 (Week 6 or time of early termination from study). Patients will be provided
      with up to two 15g tubes of ketoconazole cream (formulation F126 or F012) or matching placebo
      cream and be instructed to apply cream sparingly to affected areas of the feet once daily at
      night or in the evening for 4 weeks according to protocol specified guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unexpected discordant results between the KOH microscopy and mycological culture tests at three
    study sites in the UK.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients in the Positive Baseline Culture Set (PBCS) With Mycological Cure (MC) at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Mycological Cure (MC) was defined as having a negative potassium hydroxide (KOH) microscopy and negative fungal culture at Week 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients in the Positive Baseline Culture Set (PBCS) With Overall Cure (OC) at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Overall Cure (OC) was defined as Mycological Cure (MC) in addition to a global clinical evaluation of either 'Completely Cleared' (clearance of all signs and symptoms of Tinea pedis) or 'Marked Improvement' (significant improvement of signs and symptoms of Tinea pedis; residual signs and symptoms only), assessed at Week 6.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Ketoconazole 2% cream (formulation F126)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoconazole 2% cream (formulation F012) (Nizoral)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.</description>
    <arm_group_label>Placebo cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole 2% cream (formulation F012) (Nizoral)</intervention_name>
    <description>A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.</description>
    <arm_group_label>Ketoconazole 2% cream (formulation F012) (Nizoral)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole 2% cream (formulation F126)</intervention_name>
    <description>A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.</description>
    <arm_group_label>Ketoconazole 2% cream (formulation F126)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be co-operative, reliable and sufficiently competent to grade and record symptoms as
             requested

          -  have a clinical diagnosis of uncomplicated interdigital Tinea pedis confirmed by KOH
             microscopy

          -  Be either post-menopausal or surgically sterile, abstinent, or, if sexually active, be
             practicing an effective method of birth control before entry and throughout the study
             and have a negative urine pregnancy test at screening (applies to women only)

          -  Sign an informed consent form indicating an understanding of the purpose of and
             procedures required for the study and willingness to participate in the study

        Exclusion Criteria:

          -  Have complicated Tinea pedis defined as confluent, diffuse moccasin type tinea pedis
             of the entire plantar surface (undersurface of foot), onychomycosis (fungal nail
             infection)

          -  other dermatomycosis (fungal skin infection) requiring active treatment

          -  Have a previous sensitivity to imidazole antifungal agents or to any ingredient of the
             study medication

          -  Have a history of disallowed therapies including oral (by mouth) antifungal treatments
             within the previous 6 weeks, recent use (within 2 weeks of the study start) of topical
             antifungal agent, immunosuppressive or radiation therapy within the previous 4 weeks,
             recent use (within 2 weeks prior to screening) of other oral antibiotics, systemic
             corticosteroids or topical corticosteroids or antibiotics applied to the feet

          -  Be HIV-positive (testing will not be performed)

          -  Have uncontrolled diabetes mellitus or peripheral vascular disease requiring active
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunbury On Thames</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <results_first_submitted>February 26, 2013</results_first_submitted>
  <results_first_submitted_qc>May 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2013</results_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Pedis</keyword>
  <keyword>Ketoconazole (NIZORAL)</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Miconazole (DAKTARIN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All randomized patients (583) received at least one dose of study treatment and were included in the Safety Set. Only patients who had a positive Tinea pedis culture at baseline, ie 281 patients, were included in the Positive Baseline Culture Set (PBCS), which was the set used for analysis of the Primary and Secondary Outcome Measures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>A topical white homogenous cream identical in appearance to study drug</description>
        </group>
        <group group_id="P2">
          <title>Nizoral</title>
          <description>Ketoconazole 2% cream (formulation F012) (Nizoral)</description>
        </group>
        <group group_id="P3">
          <title>Ketoconazole</title>
          <description>Ketoconazole 2% cream (formulation F126)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="230"/>
                <participants group_id="P3" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Positive Baseline Culture Set</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>A topical white homogenous cream identical in appearance to study drug</description>
        </group>
        <group group_id="B2">
          <title>Nizoral</title>
          <description>Ketoconazole 2% cream (formulation F012) (Nizoral)</description>
        </group>
        <group group_id="B3">
          <title>Ketoconazole</title>
          <description>Ketoconazole 2% cream (formulation F126)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="230"/>
            <count group_id="B3" value="234"/>
            <count group_id="B4" value="583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="14.89"/>
                    <measurement group_id="B2" value="45" spread="13.94"/>
                    <measurement group_id="B3" value="45.9" spread="14.62"/>
                    <measurement group_id="B4" value="45" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="5.81"/>
                    <measurement group_id="B2" value="27.9" spread="4.76"/>
                    <measurement group_id="B3" value="28.3" spread="5.09"/>
                    <measurement group_id="B4" value="28.1" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients in the Positive Baseline Culture Set (PBCS) With Mycological Cure (MC) at Week 6</title>
        <description>Mycological Cure (MC) was defined as having a negative potassium hydroxide (KOH) microscopy and negative fungal culture at Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>Only patients who had a positive Tinea pedis culture at baseline, ie 281 patients, were included in the Positive Baseline Culture Set (PBCS), which was the set used for analysis of the Primary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A topical white homogenous cream identical in appearance to study drug</description>
          </group>
          <group group_id="O2">
            <title>Nizoral</title>
            <description>Ketoconazole 2% cream (formulation F012) (Nizoral)</description>
          </group>
          <group group_id="O3">
            <title>Ketoconazole</title>
            <description>Ketoconazole 2% cream (formulation F126)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients in the Positive Baseline Culture Set (PBCS) With Mycological Cure (MC) at Week 6</title>
          <description>Mycological Cure (MC) was defined as having a negative potassium hydroxide (KOH) microscopy and negative fungal culture at Week 6.</description>
          <population>Only patients who had a positive Tinea pedis culture at baseline, ie 281 patients, were included in the Positive Baseline Culture Set (PBCS), which was the set used for analysis of the Primary Outcome Measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients in the Positive Baseline Culture Set (PBCS) With Overall Cure (OC) at Week 6</title>
        <description>Overall Cure (OC) was defined as Mycological Cure (MC) in addition to a global clinical evaluation of either ‘Completely Cleared’ (clearance of all signs and symptoms of Tinea pedis) or ‘Marked Improvement’ (significant improvement of signs and symptoms of Tinea pedis; residual signs and symptoms only), assessed at Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>Only patients who had a positive Tinea pedis culture at baseline, ie 281 patients, were included in the Positive Baseline Culture Set (PBCS), which was the set used for analysis of the Secondary Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A topical white homogenous cream identical in appearance to study drug</description>
          </group>
          <group group_id="O2">
            <title>Nizoral</title>
            <description>Ketoconazole 2% cream (formulation F012) (Nizoral)</description>
          </group>
          <group group_id="O3">
            <title>Ketoconazole</title>
            <description>Ketoconazole 2% cream (formulation F126)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients in the Positive Baseline Culture Set (PBCS) With Overall Cure (OC) at Week 6</title>
          <description>Overall Cure (OC) was defined as Mycological Cure (MC) in addition to a global clinical evaluation of either ‘Completely Cleared’ (clearance of all signs and symptoms of Tinea pedis) or ‘Marked Improvement’ (significant improvement of signs and symptoms of Tinea pedis; residual signs and symptoms only), assessed at Week 6.</description>
          <population>Only patients who had a positive Tinea pedis culture at baseline, ie 281 patients, were included in the Positive Baseline Culture Set (PBCS), which was the set used for analysis of the Secondary Outcome Measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketoconazole</title>
          <description>Ketoconazole 2% cream (formulation F126)</description>
        </group>
        <group group_id="E2">
          <title>Nizoral</title>
          <description>Ketoconazole 2% cream (formulation F012) (Nizoral)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>A topical white homogenous cream identical in appearance to study drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Salivary Gland Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Loose Tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Application Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tinea Pedis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Human Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Muscle Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skeletal Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Muscle Twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin Discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated prematurely by the sponsor due to significant discrepancies between potassium hydroxide and mycological culture results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director Infectious Diseases</name_or_title>
      <organization>Jan-Cil Switzerland</organization>
      <phone>41 41 7673477</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

